亚盛医药-B（06855）今日盘中大涨8.97%，引起市场广泛关注。截至盘中11:15，该股报价39.95港元，成交额达1.54亿港元。
消息面上，亚盛医药宣布公司共有五项临床前研究进展入选2025年美国癌症研究协会（AACR）年会。这些研究包括原创1类新药奥雷巴替尼（商品名：耐立克；研发代号：HQP1351）、Bcl-2抑制剂APG-2575、FAK/ALK/ROS1三联酪氨酸激酶抑制剂APG-2449、胚胎外胚层发育蛋白（EED）抑制剂APG-5918以及IAP拮抗剂AS03157。此消息显示了公司在癌症研究领域的强劲实力和创新能力，提升了投资者对公司未来发展前景的信心。
值得注意的是，本月初亚盛医药还公布了另一项利好消息。公司的原创1类新药奥雷巴替尼（耐立克）获国家药品监督管理局（NMPA）药品审评中心（CDE）纳入"突破性治疗品种"名单，用于联合化疗一线治疗新诊断费城染色体阳性（Ph+）急性淋巴细胞白血病（ALL）患者。这是耐立克第三次获得CDE突破性治疗品种认定，进一步证实了该产品的创新性和临床价值，为公司未来的市场表现和业绩增长奠定了坚实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.